Evotec SE ADR - Asset Resilience Ratio
Evotec SE ADR (EVO) has an Asset Resilience Ratio of 3.57% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Evotec SE ADR for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Evotec SE ADR's Asset Resilience Ratio has changed over time. See EVO book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Evotec SE ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Evotec SE ADR.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $63.23 Million | 3.57% |
| Total Liquid Assets | $63.23 Million | 3.57% |
Asset Resilience Insights
- Limited Liquidity: Evotec SE ADR maintains only 3.57% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Evotec SE ADR Industry Peers by Asset Resilience Ratio
Compare Evotec SE ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Evotec SE ADR (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Evotec SE ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.73% | $90.41 Million | $1.91 Billion | +0.67pp |
| 2023-12-31 | 4.05% | $93.20 Million | $2.30 Billion | -9.53pp |
| 2022-12-31 | 13.58% | $306.61 Million | $2.26 Billion | +6.46pp |
| 2021-12-31 | 7.12% | $159.17 Million | $2.24 Billion | +3.17pp |
| 2020-12-31 | 3.95% | $72.62 Million | $1.84 Billion | +0.45pp |
| 2019-12-31 | 3.50% | $48.25 Million | $1.38 Billion | -1.79pp |
| 2018-12-31 | 5.29% | $40.82 Million | $771.88 Million | +0.11pp |
| 2017-12-31 | 5.18% | $34.56 Million | $667.27 Million | -7.32pp |
| 2016-12-31 | 12.50% | $43.92 Million | $351.37 Million | -18.85pp |
| 2015-12-31 | 31.35% | $90.46 Million | $288.54 Million | +13.01pp |
| 2014-12-31 | 18.35% | $41.21 Million | $224.60 Million | -4.74pp |
| 2013-12-31 | 23.09% | $52.49 Million | $227.38 Million | +11.30pp |
| 2012-12-31 | 11.79% | $26.57 Million | $225.43 Million | -9.30pp |
| 2011-12-31 | 21.08% | $46.01 Million | $218.21 Million | -3.65pp |
| 2010-12-31 | 24.73% | $47.45 Million | $191.86 Million | +7.38pp |
| 2009-12-31 | 17.35% | $25.43 Million | $146.60 Million | +1.47pp |
| 2008-12-31 | 15.87% | $29.03 Million | $182.90 Million | -12.09pp |
| 2007-12-31 | 27.97% | $58.14 Million | $207.88 Million | +17.98pp |
| 2006-12-31 | 9.99% | $20.53 Million | $205.53 Million | -40.25pp |
| 2005-12-31 | 50.24% | $93.50 Million | $186.11 Million | -34.42pp |
| 2004-12-31 | 84.66% | $60.03 Million | $70.91 Million | +9.14pp |
| 2003-12-31 | 75.52% | $31.51 Million | $41.73 Million | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more